Cisplatin+Vinorelbine Treatment of Recurrent or Metastatic Salivary Gland Malignancies (RMSGM): A Final Report on 60 Cases

Mario Airoldi, Massimiliano GARZARO, Fulvia Pedani, Oliviero Ostellino, Giovanni Succo, Giuseppe Riva, Matteo Sensini, Nertila Naqe, Elisa Bellini, Luca Raimondo, Giancarlo Pecorari

Research output: Contribution to journalArticlepeer-review

Abstract

Recurrent or metastatic salivary gland malignancies (RMSGM) are not suitable for conventional treatment. We report the clinical outcomes of 60 patients affected by RMSGM who were treated with DDP+VNB as a first-line or second-line scheme.
Original languageEnglish
Pages (from-to)86-90
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume40
Issue number1
DOIs
Publication statusPublished - 2017

Keywords

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Squamous Cell
  • Cisplatin
  • Female
  • Head and Neck Neoplasms
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Prospective Studies
  • Salivary Gland Neoplasms
  • Treatment Outcome
  • Vinblastine
  • Young Adult

Fingerprint

Dive into the research topics of 'Cisplatin+Vinorelbine Treatment of Recurrent or Metastatic Salivary Gland Malignancies (RMSGM): A Final Report on 60 Cases'. Together they form a unique fingerprint.

Cite this